Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab and functional adaptation in relapsing-remitting multiple sclerosis
NL-OMON40114Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of natalizumab in multiple sclerosis (MS) (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: Functional connectivity changes. Started Jun 2010; status: active, not recruiting.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON40114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40114.